Tag: Sciences

When Dr Giuseppe Colasardo, president of the Texas Health Science Center in Houston and president of the Alec Williams Endoid, suggested the global fundraising idea, he was told the school was too small to raise such funds. UTHealth was founded in 1972.

Colasardo pushed back. UTHealth Houston knew that college deans and board members needed research funding to win the war on recruiting healthcare talent. Fortunately, he also knows donors who can provide transformative gifts.

The initial target was $500 million. On April 20, Colacerdo announced that the Mission Many Faces campaign had raised a total of $534.4 million, the largest donation in Houston history.

More than 11,315 donors contributed to this record, which will contribute three points to the campaign's success: $184.5 million to educate the next generation of doctors and nurses. $182.2 million to improve access to health care in Houston. and $105 million to advance mental health and behavior.

Key prizes in 2015 included $75 million from the John B. McGovern Foundation, which was awarded to John B., in the College of Biomedical Informatics, who works to advance human health through data science. The school was named the D. Bradley McWilliams School of Biomedical Informatics at UTHealth Houston in his honour.

McWilliams, a University of Texas student who grew up in Bellaire, contemplated this gift for years before turning to computer science.

“When I decided to give an heirloom as a gift, it suited me. I give for many reasons, especially at the station where I make medical contact. I have a lot of medical problems,” he said. He said. “I can help all of them by giving to the School of Biomedical Informatics. It will help all the different schools in some way. It will lead in all areas of AI.”

Additional support from Jane and Robert Cizik in 2017 and the John S. Dunn Foundation in 2021 for the new Jane and Robert Cizik School of Nursing and the John S. Dunn Foundation. And serves as successive director of the Center for Behavioral Sciences.

The new seventh school was approved last month by the Texas Higher Education Coordinating Council and the UT System Board of Regents. The School of Behavioral Health Sciences at UTHealth Houston will offer more than 35 degree or certificate programs over the next decade.

"Our strategy is to fill this huge gap in healthcare," said Colasardo.

He added that behavioral health is called mental health. Progress in this field has been a pillar of the "Missionary Mission".

Other areas of interest include teacher recruitment, grants and research funding.

"The education and training of doctors, nurses and community health workers has always been a hotspot for people in this community," said Cosardo. “Especially for those who have taught themselves and know firsthand the difficulties of training. Most importantly, these students want to succeed.”

The campaign's focus on health care may seem self-explanatory, although Cosardo makes an important distinction.

"Everyone wants a good nanny and they want to be cared for like I was in Italy and I carried my little bag to the village," she said. “If they have serious health problems, they want to be treated here. Who hasn't dealt with Alzheimer's or depression or stroke? It doesn't save a millionaire or a billionaire or a patient in a county jail. He felt this support and this fostered connection. "

[email protected]

The Senate approved a bill changing municipal aid to unpaid municipal assistance

MarketWatch News was not involved in the creation of this content.

April 18, 2023 (The Expresswire) — Global Life Sciences BPO Market Report |In-Depth Analysis 2023 | The most important market developments, information and statistics can be found in market research reports. Life Sciences BPO Market Research Report 2023 covers 86 pages and provides exclusive information on Size, Share, Growth and Forecast vital statistics, data, information, trends and competitive landscape in this niche sector. Companies can make decisions that support their financial goals by analyzing industry financials. The Life Sciences BPO Market industry research report evaluates various aspects of the industry. By understanding the latest trends, market demands and consumer behavior, companies can make informed decisions that ensure growth and profitability. Request a sample report

MarketWatch News was not involved in the creation of this content.

Lean Six Sigma in 8 Minutes | What is Lean Six Sigma? | Lean Six Sigma | Explained Simply Learn

© Courtesy of Geekwire at the Bristol Myers-Squibb Lab in Seattle. (Photo BMS)

Seattle's life sciences workforce and federal research funding have grown rapidly since 2019, according to a new report from real estate firm CBRE.

The Seattle region ranked third among metropolitan areas for life sciences job growth, with 25% growth from 2019 to 2022. What's more, R&D jobs in the region grew by 39.3%. Only the San Francisco and Boston areas had faster job growth in this sector.

From 2019 to 2022, Seattle also had the largest increase in NIH funding of any urban region. NIH funding in the city increased by nearly 30%, reaching $1.39 billion in 2022. The University of Washington and the Fred Hutchinson Cancer Center were the top recipients of NIH funds, receiving $591.6 million and $473 million, respectively, of the .9 million received.

In 2022, life sciences funding in Seattle will top $600 million, compared to a record $1 billion in 2021. More than 1.6 million square feet of research space is under construction in the Seattle area, about a third of which is already overdue. .

RELATED: Biotech industry leaders share cautious optimism for 2023 amid economic slowdown and layoffs

"Companies in the Puget Sound region are approaching this year with cautious expectations," said Austin Arper, vice president of CBRE Life Sciences in Seattle.

"Continued economic uncertainty will slow real estate decision-making for most, but continued NIH funding of our leading research institutions will continue to drive innovation and growth in the industry," said Arper.

Seattle-based Life Science Washington recently released its 2022 Capital Investment Performance report, which lists 50 life sciences deals that have raised more than $1.19 billion for the state's industry. The team's report covers all pre-IPO deals and also includes non-venture fund investments, such as NIH campaign support and early stage angel investments.

VC deals for Seattle companies in 2022 included $93 million for Bonum Therapeutics, $96 million for Cajal Neuroscience, and $44.4 million for AltPep. Affini-T Therapeutics, which has offices in Seattle and Boston, received $175 million.

© Courtesy of Geekwire Life Sciences Venture Funding . (CBRE Graphics)

The US Life Sciences Outlook to 2023 report also assesses national trends.

The report concludes that the life sciences industry as a whole has returned to a "more normal pace" after rising in 2020 and 2021.

"Many indicators have declined from their 2020 and 2021 peaks, but are still above pre-pandemic levels. There is a lot of promising research that will drive this industry forward when lending conditions are met," said Matt Gardner, head of life sciences at CBRE.

Other information from the report:

• After surging during the pandemic, venture capital funding is now approaching pre-pandemic levels. In the first quarter of 2023, venture funding increased by 20% compared to pre-pandemic levels.
• The IPO market has cooled significantly. The total cost of the IPO exceeded $10 billion in 2021, but only exceeded $2 billion in 2022.
• Over the past decade, NIH's annual funding has increased by 62%.
• R&D spending by life sciences companies has increased by approximately 40% over the past five years.
• Last year, US life sciences companies amassed a cash reserve of $200 billion. It is lower than in the previous three years, but more than in 2018.
• Laboratory space in the top 13 US life sciences markets has grown 47% over the past five years and is expected to grow 22% over the next two years.
• Layoffs in the life sciences industry continue, with more than 50 companies announcing layoffs in the first two months of 2023 compared to the first two months of 2022. But overall, the unemployment rate among the life sciences was low, around 2%.
• Many potential treatments are in the pipeline. There are currently more than 11,500 ongoing Phase 2 and 3 clinical trials in the US, significantly more than in 2012.

© Provided by Geekwire The number of US clinical trials has increased dramatically over the past decade. (CBRE Graphics)

20 moments you won't believe until you see them

Analysts have provided the following estimates for Gilead Sciences (NASDAQ:GILD) for the most recent quarter.

Trending. An entrepreneur makes $175,000 a year selling T-shirts he never touches, working just an hour a day;

Must read. Mark Cuban says it's the key to "controlling your own destiny" and making big bucks

Based on 9 analysts providing 12-month price targets over the last 3 months, Gilead Sciences has an average price target of $92.33, with a high of $112.00 and a low of $80.00.

Below is a summary of how these 9 analysts rated Gilead Sciences over the last 3 months. The higher the number of ratings, the more analysts rate the stock positively, and the higher the number of downgrades, the more analysts rate the stock negatively.

© Provided by Benzinga Target price chart

This current average is 5.32% above the previous average price target of $87.67.

Stay informed with Gilead Sciences analyst notes.

Ratings are derived from banking and financial systems analysts or professionals reporting on specific securities or specific sectors (usually quarterly for each security). Analysts typically get their information from company conference calls and meetings, financial reports, and discussions with people important to their decision-making.

Some analysts also offer forecasts for utility metrics such as earnings, revenue, and growth estimates to provide further guidance on what to do with specific metrics. It's important to note that while stock and industry analysts are experts, they are human and can only guess their opinions to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Latest GILD ratings

See additional analyst notes on GILD

Check out the latest analyst ratings

© 2023 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.

This article on Gilead Sciences Expert Reviews originally appeared on Benzinga.com

.

Fundamental Analysis Amgen Vs GlaxoSmithKline vs Gilead | The Best Pharma Stocks to BUY | AMGN GSK GOLD

CND has raised an additional $1 million in venture funding from Top Corner Capital

Scottsdale, Arizona. , April 6, 2023 /PRNewswire/ — CND Life Sciences, a leading medical technology company developing reliable skin tests to help doctors diagnose neurodegenerative diseases such as Parkinson's disease and Lewy body dementia, today announced an initial third round of funding of $4.5 million . This follow-up round brought the company's total seed funding to $12.5 million to accelerate the commercialization of the Syn-One ^Test® , the first commercially available test capable of detecting abnormal alpha-synuclein aggregates via a simple skin biopsy. Many existing and new investors participated in this round, and Top Corner Capital provided a synchronous financing structure, demonstrating CND's solid progress and enthusiasm for the future.

"The Sin-One CND test represents a significant advance in providing clinicians and patients with disease-specific guidance that can provide more insight into optimal treatment and compromise decisions," said Patrick Lee , Managing Partner of Top Corner Capital. "Top Corner is constantly looking for promising and disruptive technology investments that will positively impact the lives of people around the world. We look forward to supporting CND's new and innovative approach to neuropathology testing and its continued growth."

Since 2021, CND has grown rapidly, growing the company from less than 10 employees to more than 60 employees in 2023 and expanding its talent pool across the country. The seed funding accelerates Syn-One's time to market with approximately 700 neurology customers in more than 40 states and collaborations with biopharmaceutical companies. Ongoing financial support from investors has helped expand the company's headquarters, which recently opened its global headquarters and lab in Scottsdale, Arizona in March 2023 .

“Continued investor engagement in each of our funds is critical to our growth as we bring critical diagnostic technologies to the CND market,” said Rick Morello , CEO of CND Life Sciences. "Revenue from the Seed 3 round, together with additional supporting funding from Top Corner Capital, will facilitate our continued development and expansion while positioning us for widespread adoption by neuroscience and biopharmaceutical companies."

CND develops and markets skin tests to help doctors across the country diagnose and treat neurological disorders such as Parkinson's disease, Lewy body dementia, multiple system atrophy, and peripheral neuropathy. Peer-reviewed studies show that many of these disorders have high rates of misdiagnosis, especially early in the disease process, often resulting in suboptimal treatment for patients and great frustration for caregivers and relatives. The Syn-One test is powered by licensed technology from Beth Israel Deaconess Medical Center in Boston .

Learn about CND Life Science and the Sin-One test
CND Life Sciences is dedicated to supporting the care of patients facing a possible diagnosis of neurodegenerative diseases and other neurological conditions. Operating a CLIA-accredited laboratory in Scottsdale, AZ , CND launched the Sin-One test in 2019 as the world's first commercially available test to detect, visualize, and quantify phosphorylated alpha-synuclein found in skin nerves. The test, which analyzes small skin biopsies collected from a patient in a doctor's office, helps diagnose Parkinson's disease, Lewy body dementia, dual system atrophy, purely autonomic failure, and synovial disorders, including REM sleep. With data demonstrating high sensitivity and specificity, the Sin-One test benefits from decades of published science from leading academic institutions in many countries. CND has research collaborations with several biopharmaceutical companies and has received three prestigious NIH SBIR grants to enhance the validation and clinical usability of Syn-One trials. For more information, visit www.cndlifesciences.com.

Disclosure: The research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke and the National Institute on Aging (NIA) of the National Institutes of Health under grant numbers R44NS117214, R44AG076072, and R44NS127696. Its contents are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health.

For media downloads, visit the original content: https://www.prnewswire.com/news-releases/cnd-life-sciences-closes-series-seed-3-round-reaches-12-5-million-in-total – equity -increase -301791200.html

Source: CND Life Sciences

Professor Xiaodong Wang

.21 Dividend” title=”BlackRock Health Sciences Trust (BME) announced a .21 dividend.” />.21 Dividend” title=”BlackRock Health Sciences Trust (BME) announced a .21 Dividend” title=”BlackRock Health Sciences Trust (BME) announced a .21 dividend.” />.21 dividend.” />.21 Dividend” title=”BlackRock Health Sciences Trust (BME) announced a .21 Dividend” title=”BlackRock Health Sciences Trust (BME) announced a .21 dividend.” />.21 Dividend” title=”BlackRock Health Sciences Trust (BME) announced a .21 Dividend” title=”BlackRock Health Sciences Trust (BME) announced a .21 dividend.” />.21 dividend.” />.21 dividend.” />

On April 3, 2023, BlackRock Health Sciences Trust's board of directors declared a regular monthly dividend of $0.21 per share ($2.56 per share). Previously, the company paid $0.21 per share.

To be eligible for the dividend, shares must be purchased prior to the ex-dividend date of April 13, 2023. Shareholders registered on April 14, 2023 will be paid on April 28, 2023.

At the current share price of $41.62, the dividend yield is 6.14%. Considering five years and running weekly samples, the average dividend yield is 5.85%, the minimum is 4.84%, and the maximum is 8.66%. The standard deviation of the results is 0.58 (n = 196).

The current dividend is 0.50 standard deviations above the historical average.

The company has a 3-year dividend growth rate of 0.07%, indicating that dividends have been increasing over time.

Learn how to receive dividends

Buy stocks. Holding shares. Selling shares. Repeat. This is share-buy content and you can easily create a share-buy calendar with Fintel.

What is stock market sentiment?

Black Rock Health Sciences Trust has 72 foundations or institutes. This is 10 owners more or 16.13% compared to the previous quarter. The average portfolio weight of all BME specialty funds is 0.25%, down 10.01%. Over the past three months, total institutional shares have increased by 9.73% to 2,521,000 shares.

What are other shareholders doing?

© Provided by Fintel BME/BlackRock Health Sciences Trust Stocks held by institutions

Elequin Capital owns 2,000 shares.

Wells Fargo owns 371,000 shares. There were no changes last quarter.

Mitra Eudaemonia has 9,000 shares. In previous filings, the company has 9,000 shares , up 0.11% . The firm increased its stake in BME Portfolio by 5.72% in the last quarter.

Advisor Group Holdings owns 90,000 shares. In its previous disclosure, the company disclosed that it holds 50,000 shares , an increase of 44.97% . Last quarter, the company reduced its BME portfolio by 72.86%.

Seamus Wealth Partners owns 13,000 shares.

Background Information BlackRock Health Sciences Trust

(This statement is provided by the company.)

BlackRock Health Sciences Trust (BME) (the "Trust")'s investment objective is to achieve total income through a combination of current income, current profitability and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing at least 80% of its assets in securities and derivatives related to the health sciences and healthcare industry under normal market conditions. The trust uses writing (selling) options to increase dividend income.

This story originally appeared on Fintel.

Proposal submission to Beacon Capital Partners for extension of Southline development in Dorchester.

A Chicago-based life sciences venture capital firm is entering the Boston market, signing a lease to renovate the former headquarters of the Boston Globe.

Portal Innovations plans to occupy 58,000 square feet of lab and office space in Beacon Capital Partners' Southline development in Dorchester, it was announced Wednesday. The company plans to expand to 22,000 square feet as the remaining space is under development and will be fully occupied in the first half of 2024.

"We are excited to bring our unique business model to a new part of Boston's life sciences ecosystem," Portal Innovations CEO John Flavin said in a press release. “Gateway is committed to supporting entrepreneurs and founders by providing a capital model designed for seed capital investment, access to strategic lab space and management expertise to venture these ventures.

The portal will work with ZoE Life Sciences and Beacon Capital to expand the space and invest in more life sciences companies. This is Portal's first location in the Boston market, with two additional offices in Atlanta and Chicago.

The lease announcement comes after the Beacon revealed plans Friday to expand the planned redevelopment of the former Boston Globe headquarters on Morrissey Street. The developer has proposed a new six-story lab and office project at 305K SF near the South Line, with an elevated walkway connecting the two, The Boston Globe first reported.

Portal isn't Southline's only venture capital. Venture capital firm Flagship Pioneering was the building's first anchor tenant, acquiring more than 45,000 square feet with apparel brand Nobull, which signed a 96,000-square-foot lease through February 2022. According to Boston, the front door of the building is 20% leased. Business magazine magazine.

Beacon has also partnered with life sciences business organization MassBio to create a 4K SF training center set to open early next year. The center will fill skills gaps in the industry and help area residents obtain certifications to help them pursue careers in the life sciences.

The Morrissey Boulevard area is starting to form its own life sciences cluster. Accordia Partners has proposed 4 million square feet of lab and office space for its Dorchester Bay City development at Center Court Mass LLC, 35-75 Morrissey Blvd. The master plan calls for the construction of four biological science buildings.

Why did life science groups appear in some cities and not in others?

In the last 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) shares. These analysts typically work for major Wall Street banks and are tasked with understanding a company's performance and predicting how its stock will trade over the next year.

These seven analysts have an average price target of $13.29, compared to ATAI Life Sciences' current price of $1.3447, indicating a bearish trend.

A summary of how these seven analysts rated ATAI Life Sciences over the past three months. The higher the rating, the more positive analysts are about the stock, and the lower the rating, the more negative analysts are about the stock.

This average price is 48.88% lower than the previous average of $26.00.

Stay up-to-date with the ATAI Life Sciences Analyst Rankings.

If you want to follow penny stock news and performance you can follow it here.

Analysts are specialists in banking and the financial system and usually report on specific stocks or sectors. These people review the company's financial statements, participate in conference calls and meetings, and talk with key people to determine what the analyst ratings for the stock should be. Typically, analysts review each stock once a quarter.

Some analysts publish forecasts on metrics such as growth, earnings and revenue estimates to provide additional guidance in their estimates. When using analyst ratings, remember that stock and industry analysts are also human and provide their opinions only to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings in Benzinga Pro along with analyst top scores.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Podcast with Christian Ungermeyer: Biotechnology and Health – Wohin geht die Reise? Hmm